Turner N T, Woolley J L, Hozier J C, Sawyer J R, Clive D
Wellcome Research Laboratories, Research Triangle Park, NC 27709.
Mutat Res. 1987 Nov;189(3):285-97. doi: 10.1016/0165-1218(87)90060-7.
Methapyrilene (MP), a sedating antihistamine, is a potent rat hepatocarcinogen which has been thought to be non-genotoxic on the basis of the negative results in a small number of short-term mutagenicity tests. The present studies show that MP is a moderately active mutagen in the L5178Y/TK +/-----TK-/- mouse lymphoma assay (MLA) in the presence of aroclor-induced rat-liver S9, and that it induces predominantly small-colony thymidine kinase-deficient (TK-/-) mutants of demonstrated chromosomal origin. 10 of 12 small colony TK-/- mutants analyzed by banded karyotype (230-band level of resolution) show aberrations to chromosome 11b, the known location of the single functional TK gene in these cells. The observed aberrations from nine of the mutants included insertions, deletions and translocations while the tenth mutant had highly rearranged, multiple copies of chromosome 11 segments. By varying the concentrations of the S9 protein and cofactors it was shown that our standard S9 composition was close to optimum for activating MP to a mutagen. The activity and stability of various lots of S9 prepared in-house or purchased from a contract laboratory revealed significant differences. The ability of 2 lots of in-house S9 to activate a standard concentration of MP increased rapidly over the first 4 weeks of liquid nitrogen storage then declined slowly over the next 16 weeks. Three separate lots of purchased S9 were essentially inactive for the first 2 weeks of liquid nitrogen storage then increased in activity thereafter; these were the only occasions in which MP was not mutagenic in our hands. The mutagenic activity of pyrilamine (PYR), a structurally related antihistamine which is far less carcinogenic in rats, but easily detected in short-term tests as being genotoxic, was also investigated in the MLA. PYR was slightly less mutagenic than MP over a comparable range of concentrations, and also induced predominantly small-colony mutants. These studies fail to adequately explain the great carcinogenic differences between these two compounds, but are consistent with the potent hepatocarcinogenicity of MP resulting through a mutagenic mechanism.
甲吡咯啉(MP)是一种具有镇静作用的抗组胺药,是一种强效的大鼠肝癌致癌物,基于少数短期致突变性试验的阴性结果,一直被认为是非基因毒性的。目前的研究表明,在多氯联苯诱导的大鼠肝脏S9存在的情况下,MP在L5178Y/TK +/-----TK-/-小鼠淋巴瘤试验(MLA)中是一种中等活性的诱变剂,并且它主要诱导已证明具有染色体起源的小集落胸苷激酶缺陷(TK-/-)突变体。通过带型核型分析(分辨率为230条带水平)对12个小集落TK-/-突变体中的10个进行分析,发现它们的11b号染色体存在畸变,11b号染色体是这些细胞中单个功能性TK基因的已知位置。在观察到的9个突变体中,畸变包括插入、缺失和易位,而第10个突变体的11号染色体片段高度重排且有多个拷贝。通过改变S9蛋白和辅因子的浓度表明,我们的标准S9组成接近将MP激活为诱变剂的最佳浓度。内部制备或从合同实验室购买的不同批次S9的活性和稳定性存在显著差异。两批内部S9激活标准浓度MP的能力在液氮储存的前4周迅速增加,然后在接下来的16周缓慢下降。购买的三批不同S9在液氮储存的前2周基本无活性,此后活性增加;这是我们实验中MP不具有诱变性的唯一情况。还在MLA中研究了吡拉明(PYR)的诱变性,PYR是一种结构相关的抗组胺药,在大鼠中的致癌性远低于MP,但在短期试验中很容易检测到具有基因毒性。在相当的浓度范围内,PYR的诱变性略低于MP,并且也主要诱导小集落突变体。这些研究未能充分解释这两种化合物之间巨大的致癌差异,但与MP通过诱变机制导致的强效肝癌致癌性是一致的。